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Abstract
The guidance issued to the pharmaceutical industry by the US Food and Drug
Administration in 2008 has led to the publication of a series of randomized,
controlled cardiovascular outcomes trials with newer therapeutic classes of
glucose-lowering medications. Several of these trials, which evaluated the
newer therapeutic classes of sodium-glucose co-transporter-2 inhibitors and
glucagon-like peptide-1 receptor agonists, have reported a reduced incidence
of major adverse cardiovascular and/or renal outcomes, usually relative to pla-
cebo and standard of care. Metformin was the first glucose-lowering agent
reported to improve cardiovascular outcomes in the UK Prospective Diabetes
Study (UKPDS) and thus became the foundation of standard care. However, as
this clinical trial reported more than 20 years ago, differences from current
standards of trial design and evaluation complicate comparison of the cardio-
vascular profiles of older and newer agents. Our article revisits the evidence
for cardiovascular protection with metformin and reviews its effects on the
kidney.
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1 | INTRODUCTION
Recent years have seen the publication of a series of large, random-
ized cardiovascular outcomes trials (CVOTs) of glucose-lowering ther-
apies.1 The transatlantic recommendations on diabetes management
from the European Association for the Study of Diabetes (EASD) and
the American Diabetes Association (ADA) have, at the time of writing,
retained metformin at the head of the algorithm for pharmacologic
management of type 2 diabetes.2 However, the debate continues on
the relative merits of metformin and the newer classes of sodium-
glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like
peptide-1 (GLP-1) receptor agonists for this position, especially for
patients who already have manifestations of cardiovascular (CV) or
renal disease.3
Metformin has been in clinical use for more than 60 years,4-6 and
was the first glucose-lowering agent associated with improved CV out-
comes in a randomized trial; however, these data, from the UK Prospec-
tive Diabetes Study (UKPDS), were published more than 2 decades ago.7
Changes in trial design, and the greater availability of trial data for the
newer glucose-lowering agents, complicate comparisons of the relative
therapeutic profiles of these agents and metformin. In this review, we
seek to re-evaluate the evidence for CV protection with metformin and
discuss its place in future diabetes management algorithms, focusing
mainly on the results of randomized controlled trials (RCTs).
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2 | METFORMIN IN ATHEROSCLEROTIC
VASCULAR DISEASE
2.1 | The UK Prospective Diabetes study
2.1.1 | Randomization of newly diagnosed,
overweight patients with type 2 diabetes to
metformin (UKPDS34)
The UKPDS remains the principal source of trial evidence to support
the presence of cardioprotective effects of metformin.7 Individuals eli-
gible for randomization had newly diagnosed type 2 diabetes with
fasting plasma glucose (FPG) >6.0 and <15 mmol/L after a 3-month
run-in on a diet high in carbohydrates and low in saturated fats.
Patients with active CV disease were excluded (recent myocardial
infarction [<1 year]; angina or heart failure; >1 major vascular event).
Figure 1 summarizes the randomization of patients in the study.7,8
Randomization was stratified partially by weight: in 15 of the
23 UKPDS centres, 1709 overweight patients (>120% “ideal
bodyweight”) were randomized to receive open-label metformin
(n = 342), “conventional” treatment (n = 411; this was essentially diet
treatment and no placebo was used), or intensive glycaemic manage-
ment with sulphonylurea (SU) or insulin (n = 961). The evaluation of
metformin in the UKPDS is sometimes mistakenly referred to as a
substudy; it is important to note that metformin was included within
the primary trial randomization as part of the original protocol,
although only in overweight patients, and only in the first 15 (of 23)
centres.7 HbA1c was generally low (mean 7.2% [55 mmol/mol] at
baseline) in this newly diagnosed population compared with most cur-
rent trials in more longstanding type 2 diabetes, and the mean body
mass index at baseline (31.4 kg/ms2) was consistent with a population
that was obese, on average.
Participants were followed for a median of 10.7 years for clinical
outcomes, which included aggregate outcomes, such as “any diabetes-
related endpoint” and “diabetes-related death”, as well as individual
outcomes (Figure 2). These two outcomes and all-cause mortality
were the three primary endpoints in the trial. Randomization to met-
formin was associated with reduced risk of any diabetes-related end-
point (by 32%, P = 0.0023), all-cause mortality (by 36%, P = 0.001)
and diabetes-related death (by 42%, P = 0.011) compared with the
control group (Figure 2). Significant reductions were also reported for
the risk of myocardial infarction (by 39%, P = 0.01) and all-cause mor-
tality (by 36%, P = 0.011). The risk of a combined macrovascular end-
point (myocardial infarction [MI], sudden death, angina, stroke and
peripheral vascular disease) was reduced by 30% (5–48) in the metfor-
min group, relative to control (P = 0.020); perhaps this is as close as
we come to a modern major adverse cardiovascular event (MACE)
outcome in the UKPDS.
2.1.2 | Rerandomization of patients
hyperglycaemic on SU to additional metformin
Patients in the main metformin analysis of the UKPDS received addi-
tional SU if they became markedly hyperglycaemic (FPG >15 mmol/L
or symptoms of hyperglycaemia), but remained within the metformin
cohort for analysis. In addition, in a UKPDS substudy, 537 patients
who became hyperglycaemic without symptoms on a maximal dose of
SU, according to a lower cut-off for glycaemia (FPG >6 mmol/L,
equivalent to 108 mg/dL), were further randomized to addition of
metformin, or to continue SU monotherapy (Figure 1).7,8 The median
follow-up in this substudy was 6.6 years. Unexpectedly, there were
significant increases for the combination versus the SU monotherapy
group in all-cause death (RR 1.60 [95% CI 1.02 to 2.52], P = 0.041)
F IGURE 1 Summary of randomized
allocation of patients to treatment in the
UK Prospective diabetes study. SU,
sulphonylurea; T2D, type 2 diabetes.
aConventional treatment policy in the
UKPDS. bThese patients were included in
the main trial analysis (UKPDS 33).
cUKPDS 34. dDefined as fasting plasma
glucose 6.1–15 mmol/L (110–270 mg/
dL) without symptoms of hyperglycaemia.
Adapted from references7,8 with
permission from Elsevier
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and diabetes-related death (RR 1.96 [95% CI 1.02 to 3.75], P = 0.039).
No other outcome was influenced significantly by addition of metfor-
min versus continued SU monotherapy, including myocardial infarc-
tion (RR 1.09 [95% CI 0.67 to 1.78], P = 0.73).
These data were difficult to interpret and may have been affected
by the play of chance. The UKPDS investigators later found that the
mortality rate in the SU monotherapy group of the combination sub-
study (8.6/1000 patient years) was markedly lower than that seen in
the main UKPDS population (11.0/1000 patient years).7,9 By way of
illustration, 35 deaths would have been predicted during 6.6 years of
follow-up on SU monotherapy, in contrast to only 26 deaths actually
observed on the metformin-SU combination (and only 14 deaths on
SU monotherapy). A Cox proportional hazards model, with current
therapies as a time-dependent variable, found a numerical but not sta-
tistically significant effect of SU + metformin on diabetes-related
death, compared with all other treatments following adjustment for
age, gender, ethnicity and FPG.7 Finally, in longer-term follow-up (see
below) there was no adverse effect of metformin + SU on mortality
outcomes, compared with SU monotherapy.10,11
2.1.3 | Long-term post-trial follow-up
UKPDS participants were followed for outcomes for a further
10 years after the end of randomized treatment.10 The between-
group difference in HbA1c during the randomized phase diminished
rapidly, with mean HbA1c similar during the rest of the follow-up
period in those previously randomized to intensive glycaemic manage-
ment with metformin or to conventional treatment. The four out-
comes for which significant risk reductions occurred in metformin-
treated patients in the randomized phase remained significantly
reduced after post-trial follow-up (Figure 2). There was no significant
effect on the incidence of stroke, peripheral vascular disease or micro-
vascular disease (when considered as individual outcomes) in either
phase.
2.2 | Other studies in type 2 diabetes
While the UKPDS was conducted exclusively in newly diagnosed
patients, another small, randomized trial (the HOME trial) enrolled a
population with more advanced type 2 diabetes.12 Here, 390 partici-
pants with an average diabetes duration of 13 years, all on insulin
treatment (for an average of ~ 6 years), were randomized to receive
metformin or placebo (in addition to insulin) for an average follow-up
of 4.3 years. The primary endpoint was a composite of three micro-
vascular and 13 macrovascular outcomes. Although the investigators
attempted to maintain glycaemic equipoise between the metformin
and placebo arms during blinded study treatment, there was a 0.4%
(2 mmol/mol) reduction in HbA1c for metformin versus placebo.
There was no significant difference between groups for the pri-
mary microvascular and macrovascular composite endpoint (HR 0.92
[0.72 to 1.18], P = 0.33, after adjustment for baseline differences in
age, gender, smoking and CV history) or the secondary composite
microvascular endpoint (HR 1.04 [0.75 to 1.44], P = 0.43, after adjust-
ment for age, gender, smoking and prior diabetic polyneuropathy).
The secondary macrovascular composite endpoint was reduced signif-
icantly by metformin versus placebo (HR 0.61 [0.40 to 0.94], P = 0.02,
adjusted as for the primary endpoint, above). In a mediation analysis,
this was partly explained by a mean reduction of 3.07 kg bodyweight
F IGURE 2 Relative risks of principal
clinical outcomes from patients
randomized to intensive glycaemic
management with metformin or to
conventional management policy in the
UKPDS, and from patients previously in
these randomized groups after 10 years
of post-trial follow-up. aComposite of
sudden death, death from hyperglycaemia
or hypoglycaemia, fatal or non-fatal
myocardial infarction, angina, heart
failure, stroke, renal failure, amputation
(≥1 digit), vitreous haemorrhage,
retinopathy requiring photocoagulation,
blindness in one eye, or cataract
extraction. bDeath from myocardial
infarction, stroke, peripheral vascular
disease, renal disease, hypoglycaemia or
hyperglycaemia, and sudden death.
Drawn from data presented in
references7,10
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in the metformin group compared with placebo. The number needed
to treat to prevent one macrovascular event was 16.
A 3-year, randomized clinical trial conducted in China compared
the effects of metformin and the SU, glipizide, on CV outcomes in
304 individuals with type 2 diabetes and pre-existing coronary artery
disease (documented prior MI or stenosis of ≥50% in a major coronary
artery).13 Average diabetes duration was ~ 6 years, and 9% were
receiving insulin. The primary outcome, an expanded MACE endpoint
(CV death, all-cause death, non-fatal MI, non-fatal stroke, or arterial
revascularization) was reduced in the metformin group relative to
glipizide (HR 0.54 [0.30 to 0.90], P = 0.026).
ADOPT (A Diabetes Outcome Progression Trial) randomized
newly diagnosed people with type 2 diabetes to double-blind treat-
ment with metformin (n = 1454), rosiglitazone (n = 1456) or
glibenclamide (glyburide, n = 1441) as initial antidiabetic pharmaco-
therapy, for 4 years.14 As this was not a prospective outcomes trial, it
is included here for completeness: its primary outcome was a measure
of glycaemic durability, with CV events (MI, stroke or heart failure)
recorded as adverse events rather than being listed as prespecified
outcomes. In this trial, 62 CV events occurred in the rosiglitazone
group, 58 in the metformin group and 41 in the glibenclamide group.
Finally, the randomized Glycemia Reduction Approaches in Diabe-
tes: A Comparative Effectiveness Study (GRADE) study (clinicaltrials.
gov NCT01794143) is a parallel group study that is evaluating
glimepiride, sitagliptin, liraglutide and insulin glargine, added to existing
metformin therapy, over a follow-up duration of 4–7 years in a popula-
tion of 5047 people with a mean duration of type 2 diabetes of
<5 years.15,16 The primary outcome relates to durability of glycaemic
control (HbA1c ≥7.0%/53 mmol/mol or ≥7.5%/59 mmol/mol); CV
events and mortality are included as secondary outcome measures. As
would be expected in this population, hypertension (67%) and hyper-
lipidaemia (72%) were prevalent at baseline. In contrast to the UKPDS,
69% and 66%, respectively, were on antihypertensive and lipid-
lowering treatment.17 However, given that GRADE was not powered
as a CVOT, its results (expected in mid-2021) will probably provide
information on CV safety in contemporary metformin-treated individ-
uals with type 2 diabetes rather than definitive conclusions on the CV
superiority or otherwise of any of the four “add-on” strategies tested.
2.3 | Studies in people with type 1 diabetes
Although metformin is indicated only for the management of type
2 diabetes, and direct extrapolation of effects to type 2 diabetes
would be speculative, effects of the drug on the CV system in patients
with type 1 diabetes are of interest in that they may help to shed light
on the mechanisms of CV protection.
CV disease is receiving increasing attention as a cause of morbidity
and mortality in people with type 1 diabetes.18 A recent, large database
study from Sweden found that, while mortality rates have been falling
in patients with type 1 diabetes since the turn of the century, the inci-
dence of CV death has remained ~ 5-fold higher compared with con-
trols matched for age, gender and location.19 A database study from
Scotland, UK, showed that the excess CV risk begins early in life:
patients with type 1 diabetes aged 20–39 years had an ~ 5-fold higher
incidence of a first CV event compared with the non-diabetic popula-
tion.20 In another study, patients with type 1 diabetes at 20 years of
age were found to face, on average, a loss of 11 years (men) or
13 years (women) of life, compared with the background population,
and CV disease accounted for the majority of this early mortality.21
The REMOVAL trial was designed to evaluate the CV effects of
metformin in a population of 428 middle-aged (≥40 years, mean age
at baseline 55 years) people with type 1 diabetes of ≥5 years duration
(mean 33 years), who had suboptimal glycaemic control
(HbA1c >7.0%, mean HbA1c 8.0%), with at least three of a list of
10 prespecified CV risk factors.22 This was clearly a population at high
CV risk, as 78% were overweight or obese (mean body mass index
28.4 kg/m2), 12% had prior CV disease, 13% were smokers, 15% had
microalbuminuria and a substantial proportion received treatment
with a statin (82%), an antihypertensive (73%) or an antiplatelet agent
(39%). A 3-month run-in phase to optimize insulin dosage and CV risk
factors was followed by randomization to metformin (target dose
2000 mg/day) or placebo for 3 years, each in addition to standard of
care for type 1 diabetes. The primary outcome was mean far-wall
carotid intima-media thickness (cIMT, a surrogate measure of the
overall burden of atherosclerosis)23 measured annually.
Modest, but significant, reductions occurred over 3 years in the
metformin versus placebo group in HbA1c (mean treatment difference
−0.13%, P = 0.006), bodyweight (−1.17 kg, P < 0.0001) and LDL cho-
lesterol (−0.13 mmol/L, P = 0.0017). The primary endpoint was not
met (mean change vs. placebo in far-wall cIMT was −0005 mm/year
[−0012 to 0002], P = 0.1664), and so the overall outcome of the trial
was neutral. However, metformin significantly reduced mean change/
year in maximal cIMT, a prespecified tertiary endpoint (−0013 mm/
year [−0024 to −0003] vs. placebo, P = 0.0093).
2.4 | Observational studies and meta-analyses
We have concentrated on evidence from randomized trials in this arti-
cle, as observational data are subject to confounding and are too
extensive to describe in detail here. In addition, larger observational
studies of metformin (ie, with data from at least 1000 subjects) have
been reviewed elsewhere.5 Statistically and clinically significant reduc-
tions in adverse CV outcomes have been observed in many of these
studies, whether metformin was compared with no treatment, lifestyle
intervention or SU. In addition, observational data indicated clinical
benefit of metformin in subjects with reduced renal function and con-
gestive heart failure.
Meta-analyses provide conflicting conclusions on whether met-
formin reduces the risk of adverse CV outcomes.24-26 The availability
of long-term evaluations of metformin is limited, which hinders effec-
tive meta-analysis. For example, one recent meta-analysis of the
effect of metformin on the incidence of MI included seven trials, with
durations ranging from 6 months to 10 years, and with numbers of
events ranging from 14 to 423.24
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A recent, very large meta-analysis included more than 1 million
patients, who participated in 40 randomized or observational evalua-
tions of metformin.27 Treatment with metformin versus no metformin
therapy was associated with reduced risk of CV death (adjusted HR
0.81 [95% CI 0.79 to 0.84]). Moreover, all-cause mortality was
reduced in the overall population (adjusted HR 0.67 [95% CI 0.60 to
0.75]), in those with prior MI (adjusted HR 0.79 [95% CI 0.68 to
0.92]), and in those with prior congestive heart failure (adjusted HR
0.84 [95% CI 0.81 to 0.87]). The frequency of CV events was also
reduced, although interestingly no significant effect was observed in
the absence of type 2 diabetes.
3 | METFORMIN IN CHRONIC KIDNEY
DISEASE
3.1 | Kidney disease markedly increases CV risk in
patients with type 2 diabetes
A recent study in 687 732 patients with type 2 diabetes showed that
18% had a first adverse cardiorenal event during 4 years of follow-
up.28 Chronic kidney disease (CKD) accounted for 36% of these
events, and was the earliest and most common CV complication of
diabetes in this population. Moreover, the appearance of CKD was
associated with a 1.8-fold increase in the risk of all-cause or CV death.
Other data from the nationally representative US National Health and
Nutrition Examination Survey (NHANES) confirm the severe adverse
impact of a diagnosis of CKD on clinical outcomes in people with dia-
betes.29 In this cohort, the age-standardized mortality rate was only
4.1% higher for people with type 2 diabetes without CKD than for
controls without either condition. However, the difference from the
control group in age-standardized mortality increased by 17.8% where
albuminuria was present, by 23.9% where glomerular filtration rate
(GFR) was abnormal, and by 47.0% where subjects had both albumin-
uria and abnormal GFR. Thus, the excess mortality associated with
diabetes was mostly accounted for by people with CKD.
3.2 | Renal safety of metformin
Intensive glycaemic control per se is widely considered to reduce the
risk of end-stage renal disease (ESRD) in type 2 diabetes, largely on
the basis of a 65% reduction in this outcome in patients randomized
to intensive versus standard blood glucose control policies in the
ADVANCE trial (HR 0.35, 95% CI 0.15 to 0.83, P = 0.01).30 However,
it should be noted that the confidence intervals are wide, as even in
this large trial with 11 140 patients randomized, there were only
27 events over 5 years of follow-up.30
Metformin was contraindicated in people with CKD (estimated
GFR [eGFR] <60 mL/min/1.73m2) for many years, however, with the
intention of mitigating a perceived association between the use of
metformin and an increased risk of lactic acidosis. Metformin
increases serum lactate levels modestly with serum lactate
concentrations usually remaining well within the normal range.31
However, as metformin is excreted unchanged via the kidney,32 a cau-
tious approach to labelling of metformin has been adopted in the set-
ting of CKD by international regulators in order to reduce the
potential for accumulation and the possibility of developing lactic
acidosis.
The current European labelling for metformin specifies that this
agent is contraindicated in patients with eGFR below 30 mL/
min/1.73m2.33 Prospective data are now available on the efficacy and
safety of metformin in people with CKD from three complementary
studies carried out in people with type 2 diabetes and CKD.34 Briefly,
study 1 involved short-term dose titration (1 week) of metformin
500–2000 mg/day in 78 patients with CKD 1–5; study 2 involved
4 months of administration of metformin 1500 mg/day to 46 patients
with CKD 3–4; and study 3 was a detailed pharmacokinetic and phar-
macodynamic study of metformin in patients with CKD 3–4. Plasma
metformin was measured 12 hours after administration (24 hours for
people with CKD 4).
Marked elevations of plasma metformin were rare in study 1, and
hyperlactataemia did not occur (summarized in Table 1). Examination
of serum metformin concentrations at different CKD stages in study
1 enabled selection of appropriate dose levels for use in study
2 (1500, 1000 and 500 mg/day for patients with CKD 3A, 3B and
4, respectively). During 4 months of metformin treatment, plasma
metformin levels remained consistently below 2.5 mg/L in most
patients (Figure 3). The pharmacokinetics of metformin changed little
across CKD stages 3A-4.
The Comparative Outcomes Study of Metformin Intervention
versus Conventional (COSMIC) Approach Study, a randomized evalua-
tion of metformin (n = 7207) versus other usual care glucose-lowering
therapies (n = 1505), also reported no cases of lactic acidosis during
1 year of follow-up.35
Given the paucity of randomized trial evidence on renal out-
comes beyond the study described above, data from key
TABLE 1 Overview of results from studies of the safety of
metformin in patients with different severities of chronic kidney
disease34
Plasma metformin concentrations correlated inversely with
glomerular filtration rate, as would be expected given the
exclusively renal elimination of metformin.
“Moderately elevated” serum metformin concentrations (>2.5 mg/L)
were observed in:
1/75 subjects at 500 mg/day
5/74 subjects at 1000 mg/day
17/68 subjects at 2000 mg/day.
“Clearly elevated” serum metformin levels (>5 mg/L) were observed
in
1/74 patients receiving metformin 1000 mg/day
2/68 patients receiving metformin 2000 mg/day.
Hyperlactataemia (serum lactate >5 mmol/L) was not observed
Only one patient had two consecutive lactate levels >2.5 mmol/L.
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observational studies are also of interest. A study based on a
community-based cohort of 75 513 subjects in Germany who were
followed from 2004 to 2017 showed that there was a significant
association between metformin use and lactic acidosis for patients
with eGFR <30 mL/min/1.73m2 (adjusted HR 2.07 [1.33 to 3.22]),
but not in those with eGFR 45–59 mL/min/1.73m2 (adjusted HR
1.16 [0.95 to 1.41]) or eGFR 30–44 mL/min/1.73m2 (adjusted HR
1.09 [0.83 to 1.44]).36 These findings were similar in a second study
using a cohort of new users of metformin and SU from the same
health system.36 A further validation using propensity score-
matched data from a commercial US database found no association
between lactic acidosis and metformin (vs. SU comparator) at any
level of eGFR.36
Lactic acidosis is an acutely life-threatening event, and it is clearly
important to minimize its occurrence. The risk of lactic acidosis when
metformin is prescribed appropriately is low, and patients with “met-
formin associated lactic acidosis” often have limited documentation of
the circulating level of metformin, or have additional risk factors for
lactic acidosis.37,38 The studies described above suggested that treat-
ment with metformin is effective and safe, with appropriate dose
adjustment, for people with CKD. Overall, the current limitation on
the use of metformin to patients with eGFR >30 mL/min/1.73m2,
with appropriate caution for people with eGFR 30–45 mL/
min/1.73m2, appears to be a pragmatic solution to ensuring the renal
safety of metformin-based therapy. Educating prescribers and metfor-
min-treated patients with CKD to follow “sick day rules” to temporar-
ily suspend intake of metformin during acute illness, especially an
episode of acute kidney injury, is also important, as acute kidney
injury or other acute, severe illnesses can markedly increase lactate
levels.39,40
Real-world data suggest the possibility of CV benefit with metfor-
min in populations with CKD. A recent retrospective analysis of pro-
pensity score-matched cohorts of 67 749 patients receiving
metformin and 28 976 receiving SU displayed a significant reduction
in the risk of MACE, with adjusted HR 0.80 (95% CI 0.75 to 0.86).41
Another observational study consisted of 508 propensity score-
matched pairs of patients receiving or not receiving metformin taken
from the population of a randomized, controlled evaluation of
darbepoetin alfa (to address anaemia) in patients with type 2 diabetes
and CKD (mean estimated eGFR at baseline was 33 mL/
min/1.73m2).42 This event-driven trial concluded after a median
follow-up duration of 29 months with a neutral outcome for the study
therapy. However, use versus non-use of metformin was associated
with a reduced risk of CV death (HR 0.49 [0.32 to 0.74]), a composite
CV endpoint (death, heart failure hospitalization, MI, stroke or myo-
cardial ischaemia; HR 0.67 [0.51 to 0.88]), a composite of renal out-
comes (ESRD or death; HR 0.77 [0.61 to 0.98]) and all-cause death
(HR 0.49 [0.36 to 0.69]). There was no increased risk of ESRD with
metformin (HR 1.01 [0.65 to 1.55]).
3.3 | Potential for renal protective effects of
metformin
As clinical data on renal outcomes in metformin-treated patients are
limited, this section will review available data from people with diabe-
tes, and will then consider experimental work in this area, including
observational data where needed. The results of such observational
studies come lower in the hierarchy of evidence than those from ran-
domized trials, but can provide additional insights where RCT data are
lacking.43
There was no significant effect of metformin versus the diet-
based control treatment on renal death or renal failure in the UKPDS,
but there were only six events of this type recorded in this newly
diagnosed population.7 The REMOVAL trial in people with type 1 dia-
betes recorded no instances of eGFR declining to <30 mL/
min/1.73m2 in either study arm.22 However, eGFR was better
maintained over time in the metformin group, with a between-group
F IGURE 3 Serum concentrations of
metformin and lactate above and below
2.5 mg/L during 4 months of
administration of metformin to people
with type 2 diabetes and chronic kidney
disease (CKD). Total daily metformin
dosages differed between patients with
CKD 3A (1500 mg), CKD 3B (1000 mg)
and CKD 4 (500 mg); see text. Drawn
from data presented in reference34
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difference of 4.0 mL/min/1.73m2 (2.19 to 5.81, P < 0.001) in favour
of metformin over 3 years.22
In the propensity-score substudy within the darbopoetin RCT
described above, the incidence of two renal outcomes was reduced in
the metformin group: a renal composite endpoint (P = 0.02) and this
endpoint plus doubling of serum creatinine (P = 0.03).42 These find-
ings may have been driven mainly by the effect of metformin on mor-
tality, as the analysis was neutral for ESRD as an individual outcome.
A study of 24 158 matched pairs of metformin users and non-users
from the Taiwan National Health Insurance database suggested a
small but significant increase in the risk of ESRD with metformin.44
Interestingly, in a recent subgroup analysis of the EMPA-REG Out-
come trial, it was suggested that renoprotection with empagliflozin
might be attenuated by background metformin therapy on the basis
that there was a non-significant trend (P for interaction = 0.07)
towards higher hazard ratios for nephropathy events with concomi-
tant metformin therapy (0.68 [95% CI 0.58 to 0.79]) compared with
no metformin therapy (0.47 [95% CI 0.37 to 0.59]).45 However, this
appears to be a misinterpretation of the data: absolute rates of inci-
dent or worsening nephropathy were lower overall in those on met-
formin (12.4% with empagliflozin vs. 16.9% on placebo) than in those
who were not on metformin (13.7% with empagliflozin vs. 24.6% on
placebo), ie, additional renoprotection with empagliflozin may have
been more difficult to detect in participants of this trial, for whom
metformin was already providing background renoprotection.
More clinical data on appropriate composite renal outcomes from
large RCTs are required in the light of these conflicting data. The Met-
formin as RenoProtector of Progressive Kidney Disease trial (RenoMet)
is evaluating metformin versus placebo in people without any type of
diabetes who have CKD 2-3B (eGFR 30–90 mL/min/1.73m2), with a
history of annual decline in eGFR of 2–15 mL/min/1.73m2 over the
preceding 3 years, and proteinuria ≤2 g/24 hours.46 The primary out-
come is time to 30% decline in eGFR. RenoMet is expected to com-
plete by the end of 2021 and will be informative with regard to the
effects of metformin on cardiorenal outcomes.
4 | DISCUSSION AND PERSPECTIVES
4.1 | Clinical outcomes trials in diabetes: then
and now
The contemporary era of CVOTs was prompted initially by concerns
over drug safety, following the publication in 2007 of a meta-analysis
of trials of a thiazolidinedione glucose-lowering agent, rosiglitazone
that suggested a significant increase in the risk of mortality (43%,
P = 0.03) and a barely non-significant increase in the risk of CV death
(64%, P = 0.06), relative to non-thiazolidinedione comparators.47
These findings were not ultimately substantiated,48 but nevertheless
highlighted a lack of oversight of CV safety within the development of
new therapies for type 2 diabetes.49 In 2008, the US Food and Drug
Administration (FDA) introduced new guidelines for the CV evaluation
of glucose-lowering treatments.50
Thus, we can divide the history of CVOTs in diabetes into two
periods. Before 2008, the evaluation of clinical outcomes in diabetes
was performed rarely, and individual trials were designed without spe-
cific reference to the design of other trials. After 2008, we have seen
numerous randomized, (almost all) placebo-controlled, outcome trials,
usually with primary outcomes of, or similar to, “three-point” or “four
point” MACE outcomes.51 Caution must always be exercised in com-
paring the results of one trial directly with another, but these studies
can be interpreted as showing that GLP-1 receptor agonists act mainly
against atherosclerotic disease to improve outcomes, while SGLT2
inhibitors may be especially effective in reducing the risk of endpoints
related to heart failure and/or renal dysfunction.52,53 It is important to
note that ~ 75% of patients randomized within recent CVOTs of
SGLT2 inhibitors or GLP-1 receptor agonists were already receiving
metformin at baseline.54
Recently updated guidance from the European Society of Cardiol-
ogy ([ESC] in collaboration with representatives of the EASD) recom-
mends that one of these agents should be prescribed irrespective of
HbA1c for patients with CV disease, or who are at high or very high
CV risk, especially where the risk of heart failure is elevated.55 Drug-
naïve patients could receive one of these antidiabetic agents as initial
glucose-lowering pharmacotherapy, in contrast to current transatlan-
tic diabetes guidelines (EASD-ADA consensus) which continue to rec-
ommend metformin as first pharmacologic treatment.2 The ESC
recommendations have proved controversial, not least because of the
increased healthcare costs implied by adding expensive, branded med-
ications to the comparatively inexpensive treatment, metformin.56
There is a need for new, well-designed clinical trials comparing met-
formin with newer agents.
But how do we consider the older generation of glucose-
lowering agents that have not had the benefit of this intensive,
FDA-mandated evaluation of outcomes? The concept of CV protec-
tion with metformin is supported by three RCTs in patients with
type 2 diabetes, which cover the natural history of diabetes from
the newly diagnosed population of the UKPDS with a low preva-
lence of CV complications at baseline,7,57 to patients with type 2 dia-
betes who already have coronary artery disease,13 to patients with
type 2 diabetes who have spent some years taking insulin.12 More-
over, data from other populations, such as people with type
1 diabetes,22,58 support the presence of antiatherosclerotic mecha-
nisms of metformin.
The randomized trials that evaluated metformin were small by
current trial standards, although the 10-year UKPDS employed a con-
siderably longer follow-up duration than most other studies. The
Kaplan–Meier curves for macrovascular outcomes in the metformin
and conventional therapy groups did not diverge until about 6 years
into the study.7 Larger studies, such as ADOPT or COSMIC (which
were not designed as outcomes trials), were of shorter duration, insuf-
ficient to show benefit. Obtaining more, and more definitive, clinical
data is always a useful answer to questions like these, and the ongoing
VA-IMPACT outcomes trial in subjects with prediabetes (even earlier
in the disease course of type 2 diabetes than the UKPDS) will provide
valuable additional data (expected to report in mid-2024).59 Table 2
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summarizes the patient population, design and outcomes of this
trial.59
4.2 | What mechanisms could account for CV
protection with metformin?
Numerous mechanisms have been proposed to account for the obser-
vations of cardioprotective effects with metformin described above. A
detailed description of these is beyond the scope of our article, and
they have been reviewed elsewhere and are summarized in
Figure 4.60-65 Briefly, RCTs or systematic reviews have shown
improvements in endothelial function66 and fibrinolysis67-69 in
metformin-treated patients that are consistent with reduced CV risk.
Effects on lipid profiles are modest, but have included reductions in
LDL cholesterol and triglycerides.70,71 Numerous findings from
experimental systems have been described, including direct cellular
antiatherogenic effects (on vascular cells and cholesterol-depositing
macrophages), improved microcirculation, reduced oxidative stress
(including that associated with deposition of advanced glycation end
products [glycoxidation]), reduced markers of inflammation (includ-
ing in patients with type 1 diabetes in the REMOVAL trial),67 effects
on the immune system, and modulation of the gut microbiome.60-65
In addition, a recently published study randomized 37 non-diabetic
patients with heart failure to metformin (mean dose 1450 mg/day)
or to placebo for 3 months, in addition to guideline-driven, maxi-
mally tolerated pharmacologic treatment for heart failure.72 Ran-
domization to metformin was associated with improved myocardial
efficiency, with reduced myocardial oxygen consumption. While this
population did not have diabetes, the authors noted that insulin
resistance plays an important part in the cardiac pathophysiology of
heart failure.
It is unclear whether weight loss on metformin contributes to CV
protection: although uncontrolled studies have described weight loss
on this agent, metformin was weight-neutral overall in several ran-
domized trials (reviewed elsewhere).73 One study (published in
abstract form only) reported a reduction in visceral adipose tissue with
metformin versus placebo.74 Finally, metformin has been observed to
increase secretion of GLP-1. It is unclear whether this is in itself a car-
dioprotective mechanism; however, post hoc analysis of three CVOTs
of dipeptidyl peptidase-4 (DPP-4) inhibitors (which protect GLP-1
from enzymic degradation) indicates numerically (but not statistically)
lower rates of CV outcomes when DPP-4 inhibitors are added to met-
formin, and (numerically) higher rates when a DPP-4 inhibitor is taken
without metformin.75 This is a hypothesis-generating observation that
requires further study.
Experimental studies are increasing understanding of the poten-
tial renoprotective effects of metformin. A recent review highlighted
potentially beneficial renal mechanisms of metformin, especially sig-
nalling through the AMP kinase (AMPK)/mTOR pathway, reduction
of endoplasmic reticulum stress, modulation of endothelial to mes-
enchymal transition, promotion of autophagy to clear away damaged
cells and organelles, inhibition of reactive oxygen species and inflam-
mation and oxidation caused by advanced glycation end products,
and reduced lipoxicity.76,77 A decline in the activity of AMPK paral-
lels the development of structural and functional abnormalities in
the kidneys of mice with experimental CKD, and metformin treat-
ment has been shown to reverse early changes of this type by
restoring AMPK activity.78 Reduced expression of the SHIP2 gene
by metformin is another candidate mechanism.79 This gene is over-
expressed in animal models of diabetes, in which it is associated with
insulin resistance and reduced glucose transport.80 SHIP2 is also
upregulated in the glomeruli of patients with type 2 diabetes, but
not in patients receiving metformin, and metformin treatment has
been associated observationally with reduced loss of renal
podocytes in patients with type 2 diabetes.80,81
TABLE 2 Overview of the ongoing VA-IMPACT trial
(NCT02915198)
Title:
Investigation of Metformin in Prediabetes on
Atherosclerotic Cardiovascular OuTcomes (VA-
IMPACT)
Design: Multicentre, prospective, randomized, double-
blind
Patients: Required to have:
Prediabetes: HbA1c ≥5.7%, <6.5% (≥39,
<48 mmol/mol) and/or
Fasting plasma glucose 100–125 mg/dL
(5.6–6.9 mmol/L) and/or 2 h post-load glucose
140–199 mg/dL (7.8–11.1 mmol/L) after a 75 g
oral glucose tolerance test
Pre-existing cardiovascular or cerebrovascular
disease
Key exclusions: Glucose-lowering therapy
Estimated glomerular filtration rate <45 mL/
min/1.73m2
Known intolerance to metformin
Pregnancy, planning pregnancy or lactating
Treatments: Metformin XR (up to 2000 mg/day)
Placebo
Outcomes: Primary: Death, non-fatal myocardial infarction
(MI), stroke, hospitalization for unstable angina,
or symptom-driven coronary revascularization
Secondary: Death, MI or stroke
Primary endpoint, peripheral arterial disease event
or hospitalization for congestive heart failure
Incidence of all components of the primary
endpoint including recurrent or multiple events
in the same participant
Each component of the primary outcome
measure, peripheral arterial disease events and
hospitalization for congestive heart failure
New or recurrent malignancy or death from a
malignancy
New diagnosis of type 2 diabetes (American
Diabetes Association criteria)
Note: Compiled from information presented in reference.59
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5 | CONCLUSIONS
The whole field of clinical trials in diabetes has changed dramatically
since 2008, leading to a number of evaluations of newer glucose-
lowering therapies that are comparatively homogenous in design,
and amenable to meta-analysis. Accordingly, it is difficult to com-
pare the actions of an older therapy such as metformin with the
results of these recent trials. Nevertheless a variety of lines of evi-
dence exist to support an antiatherosclerotic effect of metformin in
people with diabetes and a reduced risk of adverse CV outcomes in
type 2 diabetes. Although those data were collected in an earlier
era of clinical trial design, they must be taken into account in any
balanced view of the evidence. Recent evidence from clinical trials
has shown that metformin is effective and safe in people with CKD,
as long as appropriate dose adjustments are used, and use is
restricted to patients with eGFR >30 mL/min/1.73m2. Although we
have now seen more than 6 decades of continuous therapeutic use
of metformin, further data that will better define its cardioprotective
and renoprotective effects and mechanisms of metformin are set to
emerge over the next 5 years.
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